Who is sponsoring NCT03932604?

NCT03932604 is sponsored by Samsung Medical Center.

What drugs are being tested in NCT03932604?

Interventions in NCT03932604: Atrial sensing On mode.

What condition does NCT03932604 study?

NCT03932604 studies Implantable Cardioverter Defibrillator, Atrial Fibrillation, Cardiac Event, Cardiac Arrhythmia.

Is NCT03932604 still recruiting?

NCT03932604 is currently status unknown. Last updated 4 October 2021.

Last reviewed 2021-10-04 · How we verify

NCT03932604

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Atrial Sensing Capability for Better Detection of Atrial Fibrillation

Status unknown NA Last updated 4 October 2021

What this trial tests

NA trial testing Atrial sensing On mode in Implantable Cardioverter Defibrillator in 640 participants. Status unknown.

Timeline

1 June 2019

Primary endpoint
31 December 2021

31 May 2023

Quick facts

Lead sponsor	Samsung Medical Center
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	screening
Enrollment	640
Start date	1 June 2019
Primary completion	31 December 2021
Estimated completion	31 May 2023
Sites	28 locations across South Korea

Drugs / interventions tested

Atrial sensing On mode

Conditions studied

Implantable Cardioverter Defibrillator — all drugs for Implantable Cardioverter Defibrillator →
Atrial Fibrillation — all drugs for Atrial Fibrillation →
Cardiac Event — all drugs for Cardiac Event →
Cardiac Arrhythmia — all drugs for Cardiac Arrhythmia →

Sponsor

Samsung Medical Center

Who can join

19 and older, any sex, with Implantable Cardioverter Defibrillator or Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This prospective multi-center randomized controlled study aims to compare atrial fibrillation detection and inappropriate therapy according to activation of atrial sensing capability in patients with implantable cardioverter defibrillator.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The efficacy of single-lead implantable cardioverter-defibrillator with atrial sensing dipole to detect atrial fibrillation and to reduce inappropriate therapy according to atrial sensing ON or OFF: Rationale and design of the SMART-CONTROL study, a prospective multicenter random
Gwag HB, Kim HR, Park SJ, Kim J, et al · · 2022 · cited 2× · PMID 35568193 · DOI 10.1016/j.ahj.2022.05.008

Verify or expand the search:

Other recruiting trials for Implantable Cardioverter Defibrillator

Currently open trials in the same condition.

NCT05373940 — Cardioverter DefIbriIlator PlacEMent for priMary Prevention of Sudden cArdiac Death in Patients Older Than 70 Years · NA · recruiting

Other Samsung Medical Center trials

Trials by the same sponsor.

NCT07482865 — Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support · NA · not yet recruiting
NCT07467213 — Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute M · Phase 4 · not yet recruiting
NCT07530913 — Effectiveness Analysis of a Rehabilitation Exercise Platform for Living Donor Liver Transplantation Patients · NA · enrolling by invitation
NCT07500701 — Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Pro · Phase 3 · recruiting
NCT07409441 — Korea Acute Myocardial Infarction Registry · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03932604 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Samsung Medical Center
Last refreshed: 4 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03932604.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing